Showing results (191-200 of 209) with videos related to
Sort By:
Pageof 21
Urology|June 21, 2021
Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor TherapyKarl H Tully, Hendrik Jütte, Ralph M Wirtz, et al.Optics Express|October 6, 2012
Compact x-ray microscope for the water window based on a high brightness laser plasma sourceH Legall, G Blobel, H Stiel, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumabMarkus Eckstein, Philipp Erben, Maximilian C Kriegmair, et al.Nephron|June 8, 2017
Physical Activity in End-Stage Renal Disease Patients: The Effects of Starting Dialysis in the First 6 Months after the Transition PeriodNatascha J H Broers, Remy J H Martens, Tom Cornelis, et al.Plos One|August 8, 2013
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)George Pentheroudakis, Vassiliki Kotoula, Anastasia G Eleftheraki, et al.Journal for Immunotherapy of Cancer|August 27, 2021
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.Plos One|August 14, 2019
Relations of advanced glycation endproducts and dicarbonyls with endothelial dysfunction and low-grade inflammation in individuals with end-stage renal disease in the transition to renal replacement therapy: A cross-sectional observational studyRemy J H Martens, Natascha J H Broers, Bernard Canaud, et al.Cancer Chemotherapy and Pharmacology|September 9, 2011
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trialP Skarlos, C Christodoulou, K T Kalogeras, et al.Journal of Translational Medicine|February 15, 2017
Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology GroupAmanda Psyrri, Konstantine T Kalogeras, Ralph M Wirtz, et al.European Urology|November 13, 2022
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint InhibitionFranziska Erlmeier, Niklas Klümper, Laura Landgraf, et al.Pageof 21